Compare ADMA Biologics Inc (ADMA) vs Booz Allen Hamilton Holding Corporation (BAH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs Booz Allen Hamilton Holding Corporation — how do they compare? ADMA Biologics Inc trades at $9.81 (market cap $2.18B), while Booz Allen Hamilton Holding Corporation trades at $78.55 (market cap $9.37B). The key difference: Booz Allen Hamilton Holding Corporation is far larger — about 4.3× ADMA Biologics Inc's market cap, and Booz Allen Hamilton Holding Corporation pays a 3.03% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | BAH | |
|---|---|---|
Market Cap | $2.18B | $9.37B |
Sector | Health | Industrials |
52-Week High | $20.38 | $111.63 |
52-Week Low | $7.60 | $59.71 |
Enterprise Value | $2.25B | $12.99B |
Dividend Yield | — | 3.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.90, down 1.59% today, with strong profitability metrics including 64.71% gross margin and 41.9% ROE. Technical indicators show a bullish trend with support at $9-10, though RSI levels suggest overbought conditions. Recent earnings show mixed results with Q4 2025 beating expectations but Q1 and Q2 2026 missing estimates. The stock faces significant legal headwinds with multiple securities fraud lawsuits filed against the company.
Despite strong fundamentals and bullish analyst consensus (88.9% buy ratings), ADMA faces substantial legal risks from ongoing securities litigation that could impact shareholder value. The company's solid profit margins and growth trajectory provide upside potential, but investors should carefully weigh litigation risks against fundamental strength.
Booz Allen Hamilton (BAH) trades at $76.05, up 2.87% with a bullish technical signal and strong earnings beats. Recent quarters show consistent EPS outperformance, with Q2 2026 actual EPS of $1.81 beating the $1.49 estimate. The stock benefits from a discounted valuation with a P/E of 11.94 and robust cash flow growth, though revenue declined 4.2% year-over-year in Q1 2027. National security demand remains a key driver, offset by civil segment weakness.
Outlook is cautiously positive with a consensus price target of $84.67, implying 11% upside. Strengths include high ROE of 68.11% and margin expansion, but risks involve elevated debt levels and revenue volatility. Investors should weigh valuation appeal against execution risks in government contracting.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Booz Allen Hamilton Holding Corporation
Booz Allen Hamilton Holding Corp is a provider of management consulting services to the U.S. government. Other services offered include technology, such as cloud computing and cybersecurity consulting, and engineering consulting. The consulting services are focused on defense, intelligence, and civil markets. In addition to the U.S. government, Booz Allen Hamilton provides its management and technology consulting services to large corporations, institutions, and nonprofit organizations. The company assists clients in long-term engagements around the globe.
Read more on BAH →
